This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Amico, A. V. Articles by Chen, M.-H. Search for Related Content PubMed Articles by D'Amico, A. V. Articles by Chen, M.-H.

Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment Prostate-Specific Antigen Level

Anthony V. D'Amico, Marian Loffredo, Andrew A. Renshaw, Brittany Loffredo, Ming-Hui Chen

From the Departments of Radiation Oncology and Pathology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; and the Department of Statistics, University of Connecticut, Storrs, CT

Address reprint requests to Anthony V. D'Amico, MD, PhD, Brigham and Women's Hospital, Department of Radiation Oncology, 75 Francis St, L-2 Level, Boston, MA 02215; e-mail: adamico{at}lroc.harvard.edu

Purpose: We evaluated whether treatment with 6 months of androgen-suppression therapy (AST) and radiation therapy (RT) compared with RT was associated with the time to prostate-specific antigen (PSA) recurrence, prostate cancer–specific mortality (PCSM), and all-cause mortality (ACM) in men with a pretreatment PSA velocity more than 2 ng/mL/yr.

Patients and Methods: The study cohort comprised 241 men with clinically localized or locally advanced prostate cancer treated with RT and AST or RT from 1989 to 2002. Cox regression and Gray's formulation were used to assess whether treatment was associated significantly with the time to PSA recurrence or ACM and PCSM, respectively, adjusting for known prognostic factors.

Results: Despite the significantly longer median follow-up, younger age at diagnosis, higher proportion of Gleason score 7 to 10, and advanced T-category cancers, significantly lower estimates of PSA recurrence (P < .001), PCSM (P = .007), and ACM (P < .001) were observed in men who were treated using RT and AST compared with RT. Treatment with RT and AST compared with RT was associated with a longer time to PSA recurrence (adjusted hazard ratio [HR], 0.22; 95% CI, 0.14 to 0.35; P < .001), PCSM (HR, 0.23, 95% CI, 0.09 to 0.64; P = .005), and ACM (HR, 0.30; 95% CI, 0.16 to 0.58; P < .001).

Conclusion: Treatment using 6 months of AST and RT compared with RT in men with a pretreatment PSA velocity greater than 2 ng/mL/yr was associated with a longer time to PSA recurrence, PCSM, and ACM.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]

				A. V. D'Amico, M.-H. Chen, A. A. Renshaw, B. Loffredo, and P. W. Kantoff Risk of Prostate Cancer Recurrence in Men Treated With Radiation Alone or in Conjunction With Combined or Less Than Combined Androgen Suppression Therapy J. Clin. Oncol., June 20, 2008; 26(18): 2979 - 2983. [Abstract] [Full Text] [PDF]

				E. S. Antonarakis, A. L. Blackford, E. Garrett-Mayer, and M. A. Eisenberger Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review J. Clin. Oncol., November 1, 2007; 25(31): 4998 - 5008. [Abstract] [Full Text] [PDF]

				H. P. Rutz, A. J. Lomax, A. Campo, J. H. Elconin, and T. M. Pisansky Radiotherapy for Prostate Cancer N. Engl. J. Med., January 18, 2007; 356(3): 308 - 311. [Full Text] [PDF]